These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 26468691)

  • 1. Successful Treatment with Etoposide Base after an Acute Hypersensitivity Reaction to Etoposide Phosphate.
    Leguay Z; Bourneau-Martin D; Pellier I; Le Louet H; Drablier G; Lagarce L; Lainé-Cessac P
    Pediatr Blood Cancer; 2016 Mar; 63(3):571. PubMed ID: 26468691
    [No Abstract]   [Full Text] [Related]  

  • 2. Hypersensitivity reactions to etoposide phosphate.
    Sambasivan K; Mahmoud S; Kokache A; Seckl M; Savage P
    J Oncol Pharm Pract; 2014 Apr; 20(2):158-60. PubMed ID: 23740378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful treatment with etoposide phosphate in patients with previous etoposide hypersensitivity.
    Collier K; Schink C; Young AM; How K; Seckl M; Savage P
    J Oncol Pharm Pract; 2008 Mar; 14(1):51-5. PubMed ID: 18337441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful rechallenge with etoposide phosphate after an acute hypersensitivity reaction to etoposide.
    Bernstein BJ; Troner MB
    Pharmacotherapy; 1999 Aug; 19(8):989-91. PubMed ID: 10453971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide.
    Siderov J; Prasad P; De Boer R; Desai J
    Br J Cancer; 2002 Jan; 86(1):12-3. PubMed ID: 11857004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etoposide and etoposide phosphate hypersensitivity in children: Incidence, risk factors, and prevention strategies.
    Stockton WM; Nguyen T; Zhang L; Dowling TC
    J Oncol Pharm Pract; 2020 Mar; 26(2):397-405. PubMed ID: 31315549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etoposide phosphate hypersensitivity overcome using a desensitisation programme enabling optimal therapy for relapsed Hodgkin lymphoma.
    Polistena P; Tran Q; Cirillo M; O'Sullivan M; Purtill D
    Bone Marrow Transplant; 2017 Mar; 52(3):455-456. PubMed ID: 27797366
    [No Abstract]   [Full Text] [Related]  

  • 8. Early studies of etoposide phosphate, a water-soluble prodrug.
    Budman DR
    Semin Oncol; 1996 Dec; 23(6 Suppl 13):8-14. PubMed ID: 8996570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: a cancer research campaign phase I/II committee study.
    Porter D; Boddy A; Thomas H; Lind M; Newell D; Calvert AH; Robson L; Brampton M; Abrahamsen D; Winograd B
    Semin Oncol; 1996 Dec; 23(6 Suppl 13):34-44. PubMed ID: 8996574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etoposide phosphate for pediatric orthopedic malignancies after intravenous etoposide hypersensitivity.
    Brooks JP; Azmy V; Thompson A; Luon D; Prozora SD; Price C; Hsu FI
    J Oncol Pharm Pract; 2020 Jan; 26(1):228-231. PubMed ID: 30885040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe ocular and orbital toxicity after intracarotid etoposide phosphate and carboplatin therapy.
    Lauer AK; Wobig JL; Shults WT; Neuwelt EA; Wilson MW
    Am J Ophthalmol; 1999 Feb; 127(2):230-3. PubMed ID: 10030580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of etoposide phosphate (etopophos) as a 30-minute infusion on days 1, 3, and 5.
    Fields SZ; Igwemezie LN; Kaul S; Schacter LP; Schilder RJ; Litam PP; Himpler BS; McAleer C; Wright J; Barbhaiya RH
    Clin Cancer Res; 1995 Jan; 1(1):105-11. PubMed ID: 9815892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of etoposide phosphate administered as a daily 30-minute infusion for 5 days.
    Thompson DS; Greco A; Miller AA; Srinivas NR; Igwenezue KB; Hainsworth JD; Schacter LP; Kaul S; Barbhaiya RH; Garrow C
    Clin Pharmacol Ther; 1995 May; 57(5):499-507. PubMed ID: 7768072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Particular cutaneous side effects with etoposide-containing courses: is VP16 or etoposide phosphate responsible?
    Marigny K; Aubin F; Burgot G; Le Gall E; Gandemer V
    Cancer Chemother Pharmacol; 2005 Mar; 55(3):244-50. PubMed ID: 15526203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anaphylactic reaction to etoposide phosphate.
    Lindsay H; Gaynon P
    Pediatr Blood Cancer; 2012 Oct; 59(4):765. PubMed ID: 22522419
    [No Abstract]   [Full Text] [Related]  

  • 16. Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive-stage small cell lung cancer: a Minnie Pearl Cancer Research Network randomized, prospective phase II trial.
    Greco FA; Thompson DS; Morrissey LH; Erland JB; Burris HA; Spigel DR; Joseph G; Corso SW; Spremulli E; Hainsworth JD
    Oncologist; 2005 Oct; 10(9):728-33. PubMed ID: 16249353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
    Trissel LA; Martinez JF; Simmons M
    J Am Pharm Assoc (Wash); 1999; 39(2):141-5. PubMed ID: 10079649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of gender, age, and race on the pharmacokinetics of etoposide after intravenous administration of etoposide phosphate in cancer patients.
    Kaul S; Srinivas NR; Mummaneni V; Igwemezie LN; Barbhaiya RH
    Semin Oncol; 1996 Dec; 23(6 Suppl 13):23-9. PubMed ID: 8996572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose escalation study to evaluate safety, tolerability and efficacy of intravenous etoposide phosphate administration in 27 dogs with multicentric lymphoma.
    Boyé P; Serres F; Marescaux L; Hordeaux J; Bouchaert E; Gomes B; Tierny D
    PLoS One; 2017; 12(5):e0177486. PubMed ID: 28505195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etoposide treatment in recurrent medulloblastoma.
    Boor R; Huber A; Gutjahr P
    Neuropediatrics; 1994 Feb; 25(1):39-41. PubMed ID: 8208349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.